Abstract
The words “big pharma” conjure up big research infrastructure. But one of the biggest drug companies, AstraZeneca, recently decided to move nearly every aspect of neuroscience R&D outside its own walls. The scientists charged with managing the new network of drug discovery partners say the approach has brought swift access to breaking science, the freedom to rethink the fundamentals of drug discovery, and, most important, relief from the risks posed by heavy internal investment. The virtual neuroscience unit, known in-house as the neuroscience innovative medicines unit, or neuroscience iMed, was born in February 2012, when AstraZeneca unleashed massive job cuts across its R&D operations. It wielded the heaviest ax against its neuroscience unit, closing a research facility in Montreal and ending R&D in Sodertalje, Sweden. The moves wiped out internal neuroscience research in favor of a strategy of building a new drug pipeline through partnerships. The neuroscience research staff was ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.